Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Novo Nordisk sues Lilly in obesity battle; Trump takes new tariff action on generics; Novartis CEO praises Japan, blasts Germany on pricing; could pharma have a rare earth moment?; and European biotech at a crossroads.
Scrip - July 27, 2026

CareDx CEO On Precision Diagnostics Pivot, Oncology Expansion
CareDx CEO John Hanna details the twin deals — a $171.2m lab products divestiture and the up-to-$260m Naveris buy — that recast the transplant-diagnostics firm as a molecular diagnostics company betting on reimbursed, repeat-tested oncology niches led by the Medicare-covered NavDx.
Medtech Insight - July 27, 2026

Givaudan’s Fragrance Sales Offset Taste Headwinds in First Half
Givaudan's Fragrance & Beauty division generated CHF 2bn ($2.5bn) in first-half sales, growing 6.5% like-for-like and helping offset continued weakness in Taste & Wellbeing.
HBW Insight - July 24, 2026

US Consumer Health People Moves: cbdMD, Mars, Vector, NationsBenefits, Qunol, Vitamin Angels
cbdMD appoints CMO; Mars adds snack business digital, information chief; Vector peptide platform appoints president, NBA ambassador for Valor division; NationsBenefits “Food is Medicine and Health Solutions” lead; Vitamin Angels development chief; and Qunol, Tony Hawk "Move Like Champion."
HBW Insight - July 24, 2026

Bain Capital’s Vitabiotics Bet Signals Appetite For Trusted VMS Brands In High-Growth Markets
Bain Capital acquires UK supplements leader Vitabiotics in a deal that underscores private equity's growing conviction in science-backed consumer health brands. The firm will target expansion in high growth markets including China and India.
HBW Insight - July 24, 2026

Consumer Health Industry Rallies Around Prevention For International Self-Care Day
Consumer health industry associations across the globe are marking International Self-Care day with initiatives promoting the importance of prevention, health literacy and Rx-to-OTC switch.
HBW Insight - July 24, 2026

EMA Backs Three Generics Targeting Blockbuster Franchises
European regulators have backed generics to the blockbusters tafamidis and ruxolitinib, alongside riociguat, but patent and exclusivity barriers mean meaningful market entry may remain several years away.
Generics Bulletin - July 24, 2026

European Filing Moves Celltrion Closer To Cosentyx Market
Celltrion’s European filing for CT-P55 advances its bid to enter a fast-growing Cosentyx market, while streamlined trials and limited Western competition could strengthen its commercial position.
Generics Bulletin - July 24, 2026

Alvotech Says FDA Response Supports Pending Biosimilar Reviews
Alvotech says it has answered the FDA’s Reykjavik findings, with manufacturing compliance remaining pivotal to the fate of three resubmitted US biosimilar applications.
Generics Bulletin - July 24, 2026

Roche Sees No Biosimilar Spillover Threatening Vabysmo Demand
Roche believes biosimilars are eroding individual originator brands rather than the wider retinal-drug class, helping shield Vabysmo as the company lowers its 2026 loss-of-exclusivity forecast.
Generics Bulletin - July 24, 2026

European Medtech Talking Points For Late 2026
Developments in Europe’s Big Three medtech markets in June/July are set to influence policy, innovation and technology adoption in the coming 6-12 months. Running alongside are EU co-legislators’ deliberations on the EU Medical Device Regulation, the outcomes of which will be pivotal for industry.
In Vivo - July 24, 2026

EU AI Act: Clarity Or Confusion For Clinical Research?
The EU’s sweeping AI legislation presents a tangle of rules and exemptions for pharma researchers to unravel – but regulators say they want to help.
In Vivo - July 24, 2026

AI Drug Discovery’s New Bar: Proof Of Value, Not Proof Of Concept
AI drug discovery has moved past proof of concept to proof of value; the hardest bottlenecks now are the wet lab and slow scientist adoption.
In Vivo - July 24, 2026